A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients

British Journal of Cancer

Volumn 74, Issue 9, 1996, Pages 1466-1468

  Lissoni, P ^a   Paolorossi, F ^a   Tancini, G ^a   Ardizzoia, A ^a   Barni, S ^a   Brivio, F ^a   Maestroni, G J M ^b   Chilelli, M ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

Melatonin; Performance status; Tamoxifen

Indexed keywords

DACARBAZINE; ETOPOSIDE; FLUOROURACIL; FOLIC ACID; INTERFERON; MELATONIN; PINEAL BODY HORMONE; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STATISTICS; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MELANOMA; METASTASIS; ORAL DRUG ADMINISTRATION; OVARY CANCER; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; UTERINE CERVIX CARCINOMA;

EID: 0029851134     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.566     Document Type: Article

References (12)

1. BEUTLER B AND CERAMI A. (1987). Cachectin: more than a tumor necrosis factor. N. Engl. J. Med., 316, 379-385.
2. BRODER S, MUUL L AND WAIDMANN TA. (1978). Suppressor cells in neoplastic disease. J. Natl Cancer Inst., 61, 5 11.
3. INGE TH, HOOVER SK, SUSSKIND BM, BARRETT SK AND BEAR HD. (1992). Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta I. Cancer Res., 52, 1386 1392.
4. KNABBE C AND LIPPMAN ME. (1987). Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell, 48, 417-428.
5. LISSONI P, BARNI S, CRISPINO S, TANCINI G AND FRASCHINI F. (1989). Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur. J. Cancer Clin. Oncol., 25, 789-795.
6. LISSONI P, BARNI S, CATTANEO G, TANCINI G, ESPOSTI G, ESPOSTI D AND FRASCHINI F. (1991). Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies. Oncology, 40, 448-450.
7. LISSONI P, BARNI S, MEREGALLI S, FOSSATI V, CAZZANIGA M, ESPOSTI D AND TANCINI G. (1995). Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing on tamoxifen alone. Br. J. Cancer, 71, 854-856.
8. MAESTRONI GJM, CONTI A AND PIERPAOLI W. (1988). Pineal melatonin, its fundamental immunoregulatory role in aging and cancer. Ann. NY Acad. Sci., 521, 140-148.
9. POLLAK M, COSTANTINO J, POLYCHRONAKOS C, BLAUER SA, GUYDA H, REDMOND C, FISHER B AND MARGOLESE R. (1990). Effect of tamoxifen on serum insulin-like growth factor 1 levels in stage 0 breast cancer patients. J. Natl Cancer Inst., 82, 1693-1697.
10. REGELSON W AND PIERPAOLI W. (1987). Melatonin: a rediscovered antitumor hormone? Its relation to surface receptors, sex, steroid metabolism, immunologic response and chronobiological factors in tumor growth and therapy. Cancer Invest., 5, 379-385.
11. UICC. (1978). TNM. Classification of Malignant Tumors. 3rd edition. International Union Against Cancer: Geneva.
12. WHO. (1979). Handbook for Standardized Cancer Registries. WHO Offset publication No. 25. World Health Organization: Geneva.